Compare KRNT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRNT | ARVN |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 781.0M |
| IPO Year | 2015 | 2018 |
| Metric | KRNT | ARVN |
|---|---|---|
| Price | $14.36 | $11.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 23 |
| Target Price | ★ $19.75 | $17.89 |
| AVG Volume (30 Days) | 279.1K | ★ 955.1K |
| Earning Date | 02-11-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $210,041,000.00 | ★ $312,300,000.00 |
| Revenue This Year | $3.86 | $11.17 |
| Revenue Next Year | $2.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.17 | ★ 93.86 |
| 52 Week Low | $11.93 | $5.90 |
| 52 Week High | $32.09 | $21.00 |
| Indicator | KRNT | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 51.12 |
| Support Level | $14.01 | $11.86 |
| Resistance Level | $14.65 | $12.50 |
| Average True Range (ATR) | 0.49 | 0.50 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 61.83 | 39.74 |
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.